BUZZ-Corcept rises after ovarian cancer drug cuts risk of death in late-stage trial** Shares of drugmaker Corcept Therapeutics CORT.O rise 19.5% to $43.39 premarket
** Co says its experimental cancer drug, relacorilant, met the main goal in a late-stage trial in patients with platinum-resistant ovarian cancer
** Says the drug with chemotherapy showed a 35% reduction in the risk of death
** CORT previously announced results from another late-stage trial in which the combination treatment helped delay progression of a type of ovarian cancer
** Relacorilant's marketing application is currently under review by the U.S. FDA with a target action date of July 11
** CORT fell 30.9% in 2025
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments